Holen Sie sich die Stockscreener-App
3.26
2.84%
0.09
Schlusskurs vom Vortag:
$3.17
Offen:
$3.15
24-Stunden-Volumen:
51,226
Relative Volume:
1.06
Marktkapitalisierung:
$17.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-1.0689
EPS:
-3.05
Netto-Cashflow:
$-11.88M
1W Leistung:
+8.67%
1M Leistung:
-1.21%
6M Leistung:
-25.74%
1J Leistung:
-48.50%
1-Tages-Spanne:
$3.1269
$3.2808
1-Wochen-Bereich:
$3.0003
$3.2808
52-Wochen-Spanne:
$2.6838
$7.18
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Vergleichen Sie LPCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.26 | 16.05M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
| 2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
What analysts say about Lipocine Inc. stockFree Daily Trading Room Entry - jammulinksnews.com
What drives Lipocine Inc. stock priceBreakthrough stock performance - jammulinksnews.com
Lipocine Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com
Is Lipocine Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com
What makes Lipocine Inc. stock price move sharplyTrade With Low Risk Exposure - beatles.ru
How Lipocine Inc. stock performs during market volatilityFree Stock Market Forecasting Tools - Newser
Why Lipocine Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential - Investing.com Australia
Lipocine stock maintains Buy rating at H.C. Wainwright as Phase 3 trial begins - Investing.com
First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online
LPCN Begins Pivotal Phase 3 Trial for Postpartum Depression Treatment | LPCN Stock News - GuruFocus
Lipocine Begins Phase 3 Trial for LPCN 1154 - TipRanks
Lipocine to Host R&D Event on July 9 - TipRanks
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - Yahoo Finance
HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World
LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus
Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa
Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq
LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus
Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada - MarketScreener
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PR Newswire
Lipocine’s Partner Files New Drug Submission in Canada - TipRanks
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
Groundbreaking Oral Testosterone Treatment Eyes 700,000-Strong Canadian Market After FDA Success - Stock Titan
Lipocine Inc. (NASDAQ:LPCN) Short Interest Update - Defense World
Lipocine Approves Key Proposals at Shareholder Meeting - TipRanks
Q2 Earnings Forecast for Lipocine Issued By HC Wainwright - Defense World
HC Wainwright Upgrades Lipocine (NASDAQ:LPCN) to Strong-Buy - Defense World
Lipocine’s (LPCN) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):